Processa Announces $200M Private Placement And Acquisition Of Vidya Therapeutics BTK Inhibitor VT-7208; Existing Shareholders To Own About 0.9% Fully Diluted

Loading news article.

Processa Announces $200M Private Placement And Acquisition Of Vidya Therapeutics BTK Inhibitor VT-7208; Existing Shareholders To Own About 0.9% Fully Diluted | WAPE

Processa Announces $200M Private Placement And Acquisition Of Vidya Therapeutics BTK Inhibitor VT-7208; Existing Shareholders To Own About 0.9% Fully Diluted

Article summary

Related companies

Comments —